-
Article
Prognostic factors in non-small cell lung cancer: multiregression analysis in the National Cancer Center Hospital (Japan)
A total of 190 patients with unresectable non-small cell lung cancer (NSCLC) were analyzed retrospectively using eight pretreatment and three treatment-related prognostic factors in terms of influence on survi...
-
Article
Comparative study of the antitumor effect of two types of murine recombinant interferons, (β) and (γ), against B16-F10 melanoma
A comparative study of the antitumor effect of murine recombinant interferon(β) 〈Mu-rIFN(β)〉 and murine recombinant interferon(γ) 〈Mu-rIFN(γ)〉 on B16-F10 melanoma was conducted. Administration of Mu-rIFN(γ) i....
-
Article
Cytogenetic effect of carboplatin on human lymphocytes
Carboplatin, a second generation cisplatin analogue, was tested for induction of sister chromatid exchange (SCE) as well as chromosomal aberrations in human lymphocytes in vitro and in vivo. A dose-dependent e...
-
Article
Pharmacokinetics of (glycolato-0,0′)-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin
The pharmacokinetics of (glycolato-0,0′)-diammine platinum (II) (254-S; NSC 375101D), one of the new platinum analogues, was examined in a phase I study of this drug and compared with that of cisplatin and car...
-
Article
Phase II study of (glycolate-O,O′) diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer
A total of 68 patients with non-small-cell lung cancer who either had not previously been treated (38) or had undergone prior therapy (30) were treated in a phase II study of (glycolate-O,O′) diammineplatinum(II)...
-
Article
Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay
We report the predictive model for the clinical response of new platinum analogs against lung cancer by a bioassay using human lung-cancer cell lines including small-cell (SCLC) and non-small-cell lung cancer ...
-
Article
A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy
Prognostic factors for response and survival were retrospectively evaluated in 192 previously untreated patients with advanced non-small-cell lung cancer (NSCLC) who had received either vindesine plus cisplati...
-
Article
A new 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT) assay for testing macrophage cytotoxicity to L1210 and its drug-resistant cell lines in vitro
Activated by interferon γ (IFNγ)(50 U/ml) and lipopolysaccharide (50 ng/ml), mouse peritoneal macrophages were cocultured with the L1210 parental cell line (L1210/PRT) and its Adriamycin-, cisplatin-resistant ...
-
Article
7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials
The camptothecin derivative 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy camptothecin (CPT-11) has attracted the attention of clinicians because of its high antitumor activity against refractory soli...
-
Article
The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function
This study was performed to identify any relationship between age and cisplatin (CDDP) pharmacokinetics in lung cancer patients. CDDP was given at a dose of 80 mg/m2 by 1-h intravenous infusion to 23 lung cancer ...
-
Article
Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes
-
Article
Activation-Induced Apoptosis of Peripheral Lymphocytes Treated with 7-Hydroxystaurosporine, UCN-01
7-hydroxystaurosporine (UCN-01) is a new anticancer agentwhich exerts an inhibitory effect on cell cycle check points andis currently under phase I clinical trials in US and Japan.Preliminary clinical data ind...
-
Article
Problems in the development of target-based drugs
Numerous molecular targets of cancer chemotherapy have been identified based on progress made in molecular biology, and new categories of anticancer drugs have been developed. These include inhibitors for sig...
-
Article
Population pharmacokinetic modeling and model validation of a spicamycin derivative, KRN5500, in phase 1 study
Purpose: KRN5500, a novel spicamycin derivative, shows the greatest activity against a human tumor xenograft model and the highest therapeutic index among spicamycin derivatives. KRN5500 is currently under clini...
-
Article
New strategies for cancer therapy in the 21st century
The development of new anticancer drugs, radiation therapy devices, and surgical techniques has improved the survival and quality of life of cancer patients. Despite these advances, many adverse events preven...
-
Article
A phase II study of paclitaxel plus cisplatin for advanced non-small-cell lung cancer in Japanese patients
We performed a clinical phase II trial of the combination of paclitaxel and cisplatin in patients with locally advanced (stage IIIB) or metastatic non-small-cell lung cancer (NSCLC) using a 3-h infusion of pa...
-
Article
Strategy for the development of novel anticancer drugs
Progress in molecular pharmacology has demonstrated each anticancer drug to have a unique molecular target. Recent drug development has focused on compounds that specifically inhibit and/or modify tumor-specif...
-
Article
Translational and clinical studies of target-based cancer therapy
The increasing number of negative trials in cancer treatment has prompted a systematic re-evaluation of target-based drugs. It is our impression that the sensitivity of current clinical trial methodology is in...
-
Article
Translational studies for target-based drugs
The biological background for the clinical and prognostic heterogeneity among tumors within the same histological subgroup is due to individual variations in the biology of tumors. The number of investigations...
-
Chapter
Clinical Trials for Lung Cancer in Progress in Japan
